Subject(s)
Humans , Male , Female , Aged , Ferric Compounds/adverse effects , Iron Salts/adverse effects , Ferrosoferric Oxide/adverse effects , Glucaric Acid/adverse effects , Gluconates/adverse effects , Anaphylaxis/etiology , Iron-Dextran Complex/adverse effects , United States/epidemiology , Ferric Compounds/administration & dosage , Risk , Ferrosoferric Oxide/administration & dosage , Ferric Oxide, Saccharated , Glucaric Acid/administration & dosage , Gluconates/administration & dosage , Anaphylaxis/epidemiology , Injections, Intravenous , Iron-Dextran Complex/administration & dosageABSTRACT
Iron is involved in the formation as well as in the scavenging of reactive oxygen and nitrogen species. Thus, iron can induce as well as inhibit both oxidative and nitrosative stress. It also has a key role in reactive oxygen and nitrogen species-mediated apoptosis. We assessed the differences in tyrosine nitration and caspase 3 expression in the liver, heart, and kidneys of rats treated weekly with intravenous ferumoxytol, iron isomaltoside 1000, iron dextran, iron sucrose and ferric carboxymaltose (40 mg iron/kg body weight) for 5 weeks. Nitrotyrosine was quantified in tissue homogenates by Western blotting and the distribution of nitrotyrosine and caspase 3 was assessed in tissue sections by immunohistochemistry. Ferric carboxymaltose and iron sucrose administration did not result in detectable levels of nitrotyrosine or significant levels of caspase 3 vs. control in any of the tissue studied. Nitrotyrosine and caspase 3 levels were significantly (p<0.01) increased in all assessed organs of animals treated with iron dextran and iron isomaltoside 1000, as well as in the liver and kidneys of ferumoxytol-treated animals compared to isotonic saline solution (control). Nitrotyrosine and caspase 3 levels were shown to correlate positively with the amount of Prussian blue-detectable iron(III) deposits in iron dextran- and iron isomaltoside 1000-treated rats but not in ferumoxytol-treated rats, suggesting that iron dextran, iron isomaltoside 1000 and ferumoxytol induce nitrosative (and oxidative) stress as well as apoptosis via different mechanism(s).
Subject(s)
Apoptosis/drug effects , Disaccharides/adverse effects , Ferric Compounds/adverse effects , Ferrosoferric Oxide/adverse effects , Glucaric Acid/adverse effects , Iron-Dextran Complex/adverse effects , Maltose/analogs & derivatives , Tyrosine/analogs & derivatives , Administration, Intravenous , Animals , Caspase 3/biosynthesis , Disaccharides/administration & dosage , Female , Ferric Compounds/administration & dosage , Ferric Oxide, Saccharated , Ferrosoferric Oxide/administration & dosage , Glucaric Acid/administration & dosage , Iron-Dextran Complex/administration & dosage , Kidney/metabolism , Liver/metabolism , Male , Maltose/administration & dosage , Maltose/adverse effects , Models, Animal , Myocardium/metabolism , Rats , Tyrosine/metabolismSubject(s)
Iron-Dextran Complex/adverse effects , Adult , Aged , Anemia, Hypochromic/drug therapy , Arthritis/chemically induced , Bacterial Infections/etiology , Female , Humans , Infusions, Parenteral , Iron-Dextran Complex/administration & dosage , Iron-Dextran Complex/therapeutic use , Male , Middle AgedSubject(s)
Anemia, Hypochromic/prevention & control , Iron-Dextran Complex/administration & dosage , Pregnancy Complications, Hematologic/prevention & control , Adolescent , Adult , Blood Pressure/drug effects , Female , Heart Rate/drug effects , Humans , Injections, Intravenous , Iron-Dextran Complex/adverse effects , Iron-Dextran Complex/therapeutic use , Middle Aged , PregnancySubject(s)
Anemia, Hypochromic/drug therapy , Folic Acid/blood , Iron-Dextran Complex/administration & dosage , Iron/blood , Vitamin B 12/blood , Adult , Anemia, Hypochromic/blood , Female , Humans , Injections, Intravenous , Iron-Dextran Complex/adverse effects , Iron-Dextran Complex/therapeutic use , Male , Thrombophlebitis/chemically induced , Time FactorsABSTRACT
Iron-dextran complex is a valuable drug in the treatment of iron deficiency anaemias. The dangers of carcinogenicity which caused its abandonment on a wide scale during 1960 was exaggerated and the drug may safely be prescribed in the recommended dosage. It is contraindicated with haemolytic anaemia. As with all drugs, overdosage is toxic (AU)